Lexicon Pharmaceuticals | LXRX - Betriebsergebnis

Aktienkurs
2.34
Täglich Wechseln
0.34 16.75%
Monatlich
32.67%
Jährlich
233.10%
Q2 Prognose
1.96




Betriebsergebnis Veränderung Datum
Abbott USD 1.85B 399M 2026-03
Acadia Pharmaceuticals USD -4.62M 22.01M 2026-03
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
Akebia Therapeutics USD -5.45M 9.4M 2025-12
Alnylam Pharmaceuticals USD 137.59M 108.19M 2026-03
AstraZeneca USD 7.11B 4.14B 2026-03
BioMarin Pharmaceutical USD 129.65M 68.74M 2026-03
Coherus Biosciences USD -39.08M 3.65M 2025-12
Eli Lilly USD 9.78B 792M 2026-03
Esperion Therapeutics USD 85.23M 95.19M 2025-12
Halozyme Therapeutics USD -88.41M 306.33M 2025-12
Illumina USD 239M 17M 2026-03
Insmed USD -200.28M 49.43M 2026-03
Ironwood Pharmaceuticals USD 33.22M 7.58M 2024-12
J&J USD 6.62B 1.03B 2026-03
Lexicon Pharmaceuticals USD -14.78M 2.59M 2025-12
MacroGenics USD -12.1M 30.74M 2025-12
MannKind USD -76.99M 7.75M 2026-03
Merck USD -1.88B 8.12B 2026-03
Moderna USD -1.39B 531M 2026-03
Novartis USD 4.24B 171M 2026-03
PTC Therapeutics USD 45.89M 127.51M 2026-03
Puma Biotechnology USD 22.08M 24.26M 2024-09
Sarepta Therapeutics USD 358.43M 768.52M 2026-03
Thermo Fisher Scientific USD 1.91B 389M 2026-03
Ultragenyx Pharmaceutical USD -216M 102M 2026-03
United Therapeutics USD 325.8M 340.4M 2026-03
Vanda Pharmaceuticals USD -40.66M 29.66M 2024-12